I agree! It will help BSX cement their monopoly in DES even more! No other company on the planet has stents like this, it's basically a monopoly for BSX since they are the only company in the world with this alloy, which is proprietary to BSX.
Get your facts straight as it's already being discussed by doctors that this stent might not have enough outward radial force to ket it completely opened. This will have great deliverablitity but it will not be a slam dunk. A lot of this market decided by contracts now and Abbott has a lot of market share and Medtronic's new stent will grab share as well. The monopoly is long over and pricing in DES has been crushed over the last 2 years. Approval in Japan is a win!